Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

INTRODUCTION: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by surgery is the standard treatment for patients with non-metastatic muscle invasive bladder cancer (MIBC). Unfortunately, many patients are not candidates to receive cisplatin due to renal impairment. Additionally, no predictive...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez Chanza, Nieves, Soukane, Louisa, Barthelemy, Philippe, Carnot, Aurélien, Gil, Thierry, Casert, Vinciane, Vanhaudenarde, Vincent, Sautois, Brieuc, Staudacher, Lionel, Van den Brande, Jan, Culine, Stephane, Seront, Emmanuel, Gizzi, Marco, Albisinni, Simone, Tricard, Thibault, Fantoni, Jean Christophe, Paesmans, Marianne, Caparica, Rafael, Roumeguere, Thierry, Awada, Ahmad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638545/
https://www.ncbi.nlm.nih.gov/pubmed/34856936
http://dx.doi.org/10.1186/s12885-021-08990-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8638545/
https://www.ncbi.nlm.nih.gov/pubmed/34856936
http://dx.doi.org/10.1186/s12885-021-08990-3

Ejemplares similares